The FDA approved a new leukemia drug, ziftomenib, developed by Kura Oncology with the help of $330 million from a collaboration agreement with Kyowa Kirin. The drug is targeted for advanced cases of acute myeloid leukemia (AML) driven by mutations to the KMT2A gene. Ziftomenib is a menin inhibitor and is also being tested for leukemia driven by NPM1 mutations. The companies plan to develop the drug for wider use, both as an earlier line of therapy and in combination with other treatments. Kura is also developing another drug, tipifarnib, for head and neck squamous cell carcinomas.
Source link
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
